Equities

Lyra Therapeutics Inc

LYRA:NMQ

Lyra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2676
  • Today's Change0.003 / 0.98%
  • Shares traded367.39k
  • 1 Year change-90.87%
  • Beta-0.0371
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Lyra Therapeutics Inc have a median target of 1.25, with a high estimate of 2.00 and a low estimate of 0.50. The median estimate represents a 367.12% increase from the last price of 0.2676.
High647.4%2.00
Med367.1%1.25
Low86.8%0.50

Earnings history & estimates in USD

On Aug 14, 2024, Lyra Therapeutics Inc reported 2nd quarter 2024 losses of -0.74 per share.
The next earnings announcement is expected on Mar 21, 2025.
Average growth rate-31.75%
Lyra Therapeutics Inc reported annual 2023 losses of -1.26 per share on Mar 21, 2024.
Average growth rate+15.73%
More ▼

Revenue history & estimates in USD

Lyra Therapeutics, Inc. had 2nd quarter 2024 revenues of 598.00k. This bettered the 350.00k consensus of the 5 analysts covering the company. This was 45.85% above the prior year's 2nd quarter results.
Average growth rate+55.60%
Lyra Therapeutics, Inc. had revenues for the full year 2023 of 1.56m. This was 14.31% above the prior year's results.
Average growth rate+196.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.